Entries by Ayal Ronen
Trans-Pacific Health Sciences Dialogue Happening in Boston this September
The FreeMind Group is proud to support the upcoming Trans-Pacific Health Science Dialogue! Where: Boston, MA When: September 28-29, 2016 Big Players Are Making Big Bets on Biopharma in Asia Chinese investors representing more than $5.5B are looking for Trans-Pacific investments Pfizer is investing $150M in a biologics plant in China BMS expects Opdivo sales in […]
AdvaMed 2016: The MedTech Conference
The FreeMind Group is a proud supporter of AdvaMed 2016 Where: Minneapolis, MN When: October 17-19, 2016 AdvaMed 2016 is the leading MedTech Conference in North America, bringing more than 1,000 companies together for business development, capital formation, world-class educational opportunities and networking. A “must attend” event featuring a diverse attendee list that includes influential […]
RESI Boston – Come to the Hub of Life Sciences to Meet 300+ Investors
FreeMind is proud to support RESI Boston 2016 and invites you to use discount code FREEMIND100 for $100 off registration! When: Tuesday, September 13, 2016 Where: The Westin Copley Place, Boston, MA The first Redefining Early Stage Investments (RESI) Conference took place on September 16, 2013, and three years later, following highly successful events in San Francisco, Houston and […]
Attend Biospain 2016 in Bilbao, Spain this September!
Attend BioSpain 2016 Bilbao, Spain September 28-30 The FreeMind Group is a Proud Supporter of Biospain 2016 BIOSPAIN 2016 is organized by ASEBIO, the Spanish Bioindustry Association and the Basque Government through the SPRI, the Basque Business Development Agency. Biotech professionals from across Europe, America and Asia will converge on Biospain 2016 for a 3-day […]
July 22: FreeMind Presents at the North Carolina Biotech Center
Ayal Ronen, FreeMind’s Vice President, will be visiting the Research Triangle Park in North Carolina in late July and will be presenting at the NC Biotechnology Center‘s Hamner Conference Center on July 22. Ayal will provide insight into the non-dilutive funding landscape with an emphasis on the NIH, DOD, and BARDA and will describe the […]